1-3 of 3
Angelica Falkenstein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Kristin M. Savill, Adeola Y. Makinde
Journal: Blood
Blood (2022) 140 (Supplement 1): 944–946.
https://doi.org/10.1182/blood-2022-156902
Published: 2022
Journal Articles

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Sudipto Mukherjee, Kristin M. Savill, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Ali McBride
Journal: Blood
Blood (2022) 140 (Supplement 1): 10998–11000.
https://doi.org/10.1182/blood-2022-156892
Published: 2022
Journal Articles

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States

Kristin M. Zimmerman Savill, Ajeet Gajra, Kwanza Price, Jonathan K. Kish, Cherrishe Brown-Bickerstaff, Angelica Falkenstein, Talia Miller, JaLyna Laney, Sudipto Mukherjee
Journal: Blood
Blood (2021) 138 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2021-146461
Published: 2021